No abstract

OBJECTIVE:Fetuin-A is a protein secreted from the liver that inhibits arterial calcification deposition and can contribute to insulin resistance. Hyperthyroidism is also associated with insulin resistance. It is not known whether hyperthyroidism has an effect on fetuin-A levels.METHODS:We measured fetuin-A levels and homeostasis model of assessment-insulin resistance before hyperthyroidism treatment was initiated and after euthyroidism was achieved. A total of 42 patients diagnosed with hyperthyroidism were enrolled in this study. Fetuin-A, insulin, high-sensitivity C-reactive protein, fasting blood glucose, free T3 (fT3), free T4 (fT4), and thyrotropin were measured before and after euthyroidism was established.RESULTS:Basal fasting blood glucose, high-sensitivity C-reactive protein, insulin, c-peptide, homeostasis model of assessment-insulin resistance, fT3, fT4 and fetuin-A levels were significantly decreased after euthyroidism was achieved (Table 1. Basal fasting blood glucose (r:0.407, p:0.008), high-sensitivity C-reactive protein (r:0.523, p<0.0001), insulin (r:0.479, p:0.001), homeostasis model of assessment-insulin resistance (r:0.541, p<0.0001), fT3 (r:0.492, p:0.001) and fT4 (r:0.473, p:0.002) were positively correlated with basal fetuin-A levels. Basal thyrotropin levels were significantly negatively correlated (r:-0.553, p<0.0001) with basal fetuin-A levels.CONCLUSION:Our findings suggest that hyperthyroidism influences fetuin-A levels.

Objective: Osteoporosis (OP) is a disease of bones that leads increasing risk of the bone fracture, decreasing of mineral density (BMD) and deterioration of bone microarchitecture. In this study, it is aimed to assess the quality of life by using QUALEFFO-41 scale in postmenopaused women with and without osteoporosis. Material and Methods: This cross-sectional analytic survey was conducted on 280 postmenopaused women. BMD of the patients was diagnosed and osteoporosis-specific quality of life criteria (QUALEFFO-41) was used to determine the quality of life. Results: In our study, the mean age of the participants was 56.9±8.3. Of the participants, 38 (13.6%) were osteoporotic, 156 (55.7%) were osteopenic, 86 (30.7%) were normal. While the age and menopause duration increased, osteoporosis frequency increased (p<0.001), but while body mass index (BMI) increased, osteoporosis frequency decreased (p<0.001). When their activities increased, osteoporosis frequency decreased (p=0.006) and osteoporosis frequency was higher in having previous fracture history (p=0.015). When the women's quality of life compared with the results of DXA, a negative, moderate significant relationship was found. The quality of life was decreasing in the individuals having older age and lower education level. Quality of life of was higher in workers, individuals having high income level, having exercise and high activities (p<0.001). Conclusion: While OP was higher with aging, menopause duration, having previous fracture history; OP was lower for high activitiy and for high BMI. While the quality of life was higher in workers, individuals having high income, having exercise regularly; the quality of life was lower in aging, OP and lower educational level. Key Words: Osteoporosis, postmenopausal woman, quality of life, QUALEFFO-41 ÖzetAmaç: Osteoporoz (OP) kemik mineral yoğunluğunda (KMY) azalmaya, kemik mikro mimarisinde bozulmaya ve kırık riskinde artmaya yol açan bir kemik hastalığıdır. Bu çalışmada osteoporozu olan ve olmayan postmenopozal kadınlarda QUALEFFO-41 ölçeği ile yaşam kalitesinin değerlendirilmesini amaçladık. Gereç ve Yöntemler: Kesitsel tipteki bu analitik araştırma menopozda olan 280 kadında yapıldı. Hastaların KMY'si ölçüldü ve yaşam kalitesini değerlendirmek için osteoporoza özgü yaşam kalitesini belirleyen QUALEFFO-41 ölçeği uygulandı. Bulgular: Çalışmamızda kadınların yaş ortalamaları 56,9±8,3 idi. Olguların KMY'leri değerlendirildiğinde 38'sinde (%13,6) osteoporoz, 156'sında (%55,7) osteopeni bulundu, 86'sı (%30,7) normal idi. Yaş ve menopoz süresi arttıkça osteoporoz sıklığı artarken (p<0,001), beden kütle indeksi (BKİ) arttıkça osteoporoz sıklığı azalıyordu (p<0,001). Aktiviteleri arttıkça osteoporoz sıklığı azalıyordu (p=0,006) ve geçirilmiş kırık öyküsü olanlarda osteoporoz daha fazla idi (p=0,015). Kadınların KMY değerleri ile yaşam kalitesi karşılaştırıldığında negatif yönde, orta derecede anlamlı bir ilişki bulundu. İleri yaş ve düşük eğitimlilerde yaşam kalitesi azalıyordu. Çalışanlarda, gelir düzeyi yüks...

No abstract

Background:The objective of this study was to evaluate the effect of weight loss with hypocaloric diet and orlistat treatment in addition to hypocaloric diet on gut-derived hormones ghrelin and obestatin.Materials and Methods:A total of 52, euglycemic and euthyroid, obese female patients were involved in the study. The patients were assigned to two groups: Group 1 (n = 26) received hypocaloric diet alone and Group 2 (n = 26) received orlistat in addition to hypocaloric diet for 12 weeks. Anthropometric measurements, serum lipid, insulin levels, and obestatin and ghrelin values were assessed at the beginning of the study and after 12 weeks of therapy.Results:Baseline clinical characteristics and laboratory parameters including serum ghrelin and obestatin concentrations and ghrelin/obestatin ratio were similar between the two groups. After 12 weeks, mean change in BMI, fat mass, and fat-free mass (FFM) were −1.97 ± 1.56 kg/m2 (P = 0.003), −2.63% ±2.11% (P = 0.003), and −1.06 ± 0.82 kg (P = 0.003), respectively, in Group 1. In Group 2, mean change in BMI was −2.11 ± 1.24 kg/m2 (P = 0.001), fat mass was −3.09% ±2.28% (P = 0.002), and FFM was −1.26 ± 0.54 kg (P = 0.001). However, fasting glucose, lipid, and insulin levels did not change in Group 1. Furthermore, except serum high-density lipoprotein cholesterol and triglyceride levels, no significant change was observed in Group 2. Although serum ghrelin and obestatin concentrations increased significantly in both groups (Group 1: pGhrelin: 0.047, pobestatin: 0.001 and Group 2: pGhrelin: 0.028, pobestatin: 0.006), ghrelin/obestatin ratio did not change significantly. When the changes in anthropometric assessments and laboratory parameters were compared, no significant difference was observed between the two groups. Furthermore, no correlation was observed between ghrelin or obestatin and any other hormonal and metabolic parameters.Conclusion:Weight loss with diet and diet plus orlistat is both associated with increased ghrelin and obestatin concentrations.